Evidence map›Paper›PMID 35865615›Full record

ReviewRSC advances2022

Advances and emerging challenges in MXenes and their nanocomposites for biosensing applications.

Zaheer Ud Din Babar, Bartolomeo Della Ventura, Raffaele Velotta, Vincenzo Iannotti

Abstract readReview
In one paragraph

Review in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. MoSMikrochimica acta · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zaheer Ud Din BabarScuola Superiore Meridionale (SSM), University of Naples Federico II Largo S. Marcellino, 10 80138 Italy.ORCID https://orcid.org/0000-0003-3293-6244
Bartolomeo Della VenturaDepartment of Physics "E. Pancini", University of Naples Federico II Via Cintia 26 80126 Naples Italy viannotti@unina.it.ORCID https://orcid.org/0000-0003-2920-6187
Raffaele VelottaDepartment of Physics "E. Pancini", University of Naples Federico II Via Cintia 26 80126 Naples Italy viannotti@unina.it.ORCID https://orcid.org/0000-0003-1077-8353
Vincenzo IannottiDepartment of Physics "E. Pancini", University of Naples Federico II Via Cintia 26 80126 Naples Italy viannotti@unina.it.ORCID https://orcid.org/0000-0001-7229-5045

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Two-dimensional materials have unique properties and their better functionality has created new paradigms in the field of sensing. Over the past decade, a new family of 2D materials known as MXenes has emerged as a promising material for numerous applications, including biosensing. Their metallic conductivity, rich surface chemistry, hydrophilicity, good biocompatibility, and high anchoring capacity for biomaterials make them an attractive candidate to detect a variety of analytes. Despite such notable properties, there are certain limitations associated with them. This review aims to present a detailed survey of MXene's synthesis; in particular, their superiority in the field of biosensing as compared to other 2D materials is addressed. Their low oxidative stability is still an open challenge, and recent investigations on MXene's oxidation are summarized. The hexagonal stacking network of MXenes acts as a distinctive matrix to load nanoparticles, and the embedded nanoparticles can bind an excess number of biomolecules (

Identifiers

PMID35865615
PMCPMC9258029

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.